Research

*August 2024* A fast track designation has been granted to Deltacel (KB-GDT-01) in combination with low-dose radiation therapy by the FDA. This indication is for patients with metastatic non–small cell lung cancer (NSCLC) who have progressed on 2 or more prior lines of standard-of-care therapy. The agent is currently undergoing…

*August 2024* The discovery of EGFR as a driver mutation and the development of medications to take advantage of this mutation changed the treatment of non-small cell lung cancer (NSCLC) forever. Not only did it vastly improve outcomes for patients with this subset of cancers, it opened the door for…

*June 2024* In this video, experts provide perspectives (and pros and cons) on recent data from the PALOMA-3 study investigating subcutaneous amivantamab in patients with refractory EGFR-mutated advanced non–small cell lung cancer. Watch here.

*December 2023* Background Long QT syndrome (LQTS) has been reported in older patients with advanced non-small cell lung cancer (NSCLC) following the use of osimertinib, the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). However, there have not been analytic epidemiology studies on this topic. We aimed to compare the…

*July 2024* What are the key takeaways? Results from the study showed that 55% of participants responded to treatment with T-DXd. The median length of time participants continued to respond to T-DXd was 9.3 months. After receiving T-DXd, 92% of participants had disease control. After receiving T-DXd, half of the…

*August 2024* Lung cancer varies between Caucasians and Asians. There have been differences recorded in the epidemiology, genomics, standard therapies and outcomes, with variations according to the geography and ethnicity which affect the decision for optimal treatment of the patients. To better understand the profile of lung cancer in Southeast…

*July 2024* In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patients with molecular driven non-small cell lung cancer. Guests: Dr. Erin Schenk is an Assistant Professor of…

*August 2024* Highlights •TKI have revolutionized the course of advanced NSCLC with EGFR common mutation. •Tumor heterogeneity and acquired resistance mechanisms are unavoidable limits. •Multiple novel treatment strategies based on various combinations have emerged. •Treatment strategy should be based on the clinical and biological profile. •Taking patients preferences into account is…

*July 2024* Health Canada has approved osimertinib (Tagrisso) in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R mutations.1 The regulatory decision was supported by data from the phase 3…

*June 2024* Drs. Benjamin Levy, Antoinette (Toni) Wozniak, and Isabel Preeshagul discussed the news from this year’s ASCO Annual Meeting – a premier scientific event for oncology professionals, patient advocates, industry representatives, and the media. ASCO, or American Society of Clinical Oncology, is a leading organization for health care professionals…